Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | PARP1 | P09874 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2196700 | 0.99 | MEN1 (0.47) | MEN1KMT2AMGLLHCRTR1HCRTR2 | |
| SCHEMBL12420769 | 0.89 | MGLL (0.58) | MEN1KMT2AMGLLSIGMAR1PARP1 | |
| SCHEMBL2197433 | 0.89 | HCRTR1 (0.45) | MEN1KMT2AMGLLHCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL2196480 | 0.88 | HCRTR1 (0.44) | MEN1KMT2AMGLLHCRTR1HCRTR2 | |
| SCHEMBL25120379 | 0.87 | NPC1 (0.54) | MEN1KMT2AMGLLHCRTR1HCRTR2 | |
| SCHEMBL30318932 | 0.87 | F10 (0.48) | MEN1KMT2AMGLLHCRTR1HCRTR2 | |
| SCHEMBL2194541 | 0.87 | F10 (0.48) | MEN1KMT2AMGLLHCRTR1HCRTR2 | |
| SCHEMBL12735909 | 0.86 | HPGD (0.54) | MEN1KMT2ASIGMAR1HRH3ALDH1A1 | |
| SCHEMBL13806531 | 0.85 | NFE2L2 (0.41) | HCRTR1HCRTR2HRH3ALDH1A1 | |
| SCHEMBL25120365 | 0.84 | MGLL (0.49) | MEN1KMT2AMGLLHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023049808-A2 | SMALL MOLECULE INHIBITORS OF TEAD-YAP | THE GENERAL HOSPITAL CORPORATION (US) | 2023-03-30 | — | — | WO | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2065369-A1 | UREA COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | MEN1 4707/4885KMT2A 1156/4885MGLL 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.